Results 11 to 20 of about 44,270 (170)

Role of D1/D2 dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats

open access: yesBiomolecules & Biomedicine, 2013
While opioid receptors have been implicated in the development of tolerance, the subsequent mechanisms involved in these phenomena have not been completely understood.
Ercan Ozdemir   +2 more
doaj   +1 more source

The dopamine D1-D2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in basal ganglia

open access: yesFrontiers in Neuroanatomy, 2011
Dopaminergic signaling within the basal ganglia has classically been thought to occur within two distinct neuronal pathways; the direct striatonigral pathway which contains the dopamine D1 receptor and the neuropeptides dynorphin and substance P, and the
Melissa L. Perreault   +7 more
doaj   +1 more source

Dysregulation of dopamine neurotransmission in the nucleus accumbens in immobilization-induced hypersensitivity

open access: yesFrontiers in Pharmacology, 2022
Cast immobilization causes sensory hypersensitivity, which is also a symptom of neuropathic pain and chronic pain. However, the mechanisms underlying immobilization-induced hypersensitivity remain unclear.
Yuki Kishikawa   +7 more
doaj   +1 more source

Cortical Dopamine Transmission as Measured with the [11C]FLB 457 - Amphetamine PET Imaging Paradigm Is Not Influenced by COMT Genotype. [PDF]

open access: yesPLoS ONE, 2016
Basic investigations link a Val158Met polymorphism (rs4680) in the catechol-O-methyltransferase (COMT) gene to not only its enzymatic activity, but also to its dopaminergic tone in the prefrontal cortex.
Rajesh Narendran   +7 more
doaj   +1 more source

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

open access: yesClinical Parkinsonism & Related Disorders, 2023
Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson   +4 more
doaj   +1 more source

Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence [PDF]

open access: yesBrazilian Journal of Medical and Biological Research, 2015
Meningiomas are common, usually benign tumors, with a high postoperative recurrence rate. However, the genesis and development of these tumors remain controversial.
G. Trott   +5 more
doaj   +3 more sources

Antisera specific for D2 dopamine receptors [PDF]

open access: yesBiochemical Journal, 1993
Antisera have been raised against two peptides from the sequence of D2 dopamine receptors: peptide 1 from the predicted second extracellular loop and peptide 2 from the predicted third intracellular loop. The antisera recognize specifically a 95 kDa band in Western blots of several bovine brain regions, which corresponds to the denatured D2 dopamine ...
P L, Chazot, A J, Doherty, P G, Strange
openaire   +2 more sources

Initial d2 dopamine receptor sensitivity predicts cocaine sensitivity and reward in rats. [PDF]

open access: yesPLoS ONE, 2013
The activation of dopamine receptors within the mesolimbic dopamine system is known to be involved in the initiation and maintenance of cocaine use. Expression of the D2 dopamine receptor subtype has been implicated as both a predisposing factor and ...
Kathryn E Merritt, Ryan K Bachtell
doaj   +1 more source

Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders: Proteins Interacting With the Third Cytoplasmic Loop of Dopamine D2 and D3 Receptors

open access: yesJournal of Pharmacological Sciences, 2010
Among the various dopamine receptors, D2-like receptors (D2R, D3R, and D4R) are characterized by a large third cytoplasmic loop, a short carboxyl-terminal tail, and the ability to activate inhibitory G proteins.
Norifumi Shioda   +2 more
doaj   +1 more source

Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model

open access: yesNeurobiology of Disease, 2004
Brain cannabinoid CB1 receptors are expressed in neural areas that contribute to movement such as basal ganglia, where they co-localize with dopamine D1 and D2 receptors.
Fadwa El Banoua   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy